


## CLAIMS

1. N-phenyl-2-pyrimidine-amine derivative represented by the following formula (1):

5




and its salt, in which

R<sub>1</sub> represents 3-pyridyl or 4-pyridyl,

R<sub>2</sub> and R<sub>3</sub> each represent hydrogen or lower alkyl,

R<sub>6</sub> or R<sub>7</sub> represents a radical having the following formula (2):

10



15

wherein X represents oxygen or NH, n=0 or 1, and R<sub>9</sub> represents aliphatic having 5 to 10 carbon atoms, or represents 5 to 7 membered saturated or unsaturated monocyclic radical, or bi- or tri-cyclic radical optionally combined with benzene ring, each of which has 1 to 3 hetero atoms selected from a group consisting of nitrogen, oxygen and sulfur, or represents piperazinyl or homopiperazinyl each of which is substituted by lower alkyl, and

20


R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub>, and R<sub>8</sub> each represent hydrogen, or one or two thereof each represent halogen, lower alkyl, or lower alkoxy when R<sub>6</sub> represents the radical of the above formula (2), or one or two of R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>8</sub> each represent halogen, lower alkyl, or lower alkoxy when R<sub>7</sub> represents the radical of the above formula (2), provided that R<sub>6</sub> or R<sub>7</sub> represents a radical of formula (2) wherein n=0 and R<sub>9</sub> is 4-methylpiperazine, then one or more of R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub>, and R<sub>8</sub>, or one or more of R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>8</sub> are halogen.

2. The compound of claim 1 wherein

R<sub>1</sub> represents 3-pyridyl,

R<sub>2</sub> and R<sub>3</sub> each represent hydrogen,

5 R<sub>6</sub> or R<sub>7</sub> represents a radical having the following formula (2):



wherein X represents NH, n=0 or 1, and R<sub>9</sub> represents piperidine, 4-methylhomopiperazine, or 4-methylpiperazine, and



10 R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub>, and R<sub>8</sub> each represent hydrogen, or one or two thereof each represent fluoro, methyl, or methoxy when R<sub>6</sub> represents the radical of the above formula (2), or one or two of R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>8</sub> each represent fluoro, methyl, or methoxy when R<sub>7</sub> represents the radical of the above formula (2).

3. The compound of claim 1 wherein R<sub>1</sub> represents 3-pyridyl, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub>, and


15 R<sub>8</sub> each represent hydrogen, and R<sub>6</sub> represents the radical of formula (2) wherein n=0 and R<sub>9</sub> represents 4-methylhomopiperazine, or n=1, X represents NH, and R<sub>9</sub> represents 4-methylpiperazine.

20 4. The compound of claim 1 wherein R<sub>1</sub> represents 3-pyridyl, R<sub>2</sub> and R<sub>3</sub> each represent hydrogen, R<sub>4</sub> represents methyl, R<sub>5</sub>, R<sub>6</sub> and R<sub>8</sub> each represent hydrogen, and R<sub>7</sub> represents the radical of formula (2) wherein n=1, X represents NH, and R<sub>9</sub> represents 4-methylpiperazine.



25 5. A process for preparing the compound of formula (1) as defined in claim 1, which comprises reacting a compound represented by the following formula (3a) or (3b):



wherein R<sub>1</sub> to R<sub>8</sub> are as defined in claim 1, with a compound represented by the following formula (4):





wherein L represents a leaving group, to produce a compound represented by the following formula (5a) or (5b):



10 wherein R<sub>1</sub> to R<sub>8</sub> and L are as defined above, and reacting the compound of formula (5a) or (5b) with a compound represented by the following formula (6):



wherein X, n, and R<sub>9</sub> are as defined in claim 1, to give a compound represented by the following formula (1a) or (1b):



5

wherein R<sub>1</sub> to R<sub>8</sub>, X, n, and R<sub>9</sub> are as defined above.

6. A pharmaceutical composition for the treatment of lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer, which comprises an effective amount of the compound of formula (1) or its salt as defined in claim 1 as an active ingredient together with pharmaceutically acceptable inert carriers.

10

15 7. The composition of claim 6 which is used as an oral preparation.

8. The composition of claim 6 which is used as an injection.

20 9. A method of treating lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer,

which comprises having a host in need of such treatment ingest an amount of the compound of formula (1) or its salt as defined in claim 1 effective to provide such treatment.